<DOC>
	<DOCNO>NCT01482884</DOCNO>
	<brief_summary>The study design evaluate clinical efficacy safety tralokinumab compare placebo . Investigational product administer subcutaneous injection . All patient continue background therapy ulcerative colitis per local standard care addition investigational product .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Tralokinumab Patients With Active , Moderate-to-severe Ulcerative Colitis</brief_title>
	<detailed_description>A phase IIa , randomise , double-blind , placebo-controlled , parallel-arm , multicenter study evaluate efficacy safety tralokinumab ( CAT-354 ) , recombinant human monoclonal antibody direct interleukin-13 ( IL-13 ) , add-on therapy , clinical response patient active , moderate-to-severe , ulcerative colitis</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosed ulcerative colitis least 90 day prior randomisation . Men woman age 18 75 year . Nonhospitalized patient moderatesevere ulcerative colitis treat stable background UC therapy ( e.g . contain 5aminosalicylates , and/or low dose glucocorticosteroids , and/or purine analogue ) prior randomization . Females childbearing potential sexually active nonsterilized male partner must use highly effective contraception Day1 . Nonsterilized male sterilize male â‰¤1 year postvasectomy sexually active female partner childbearing potential must use highly effective method contraception . Pregnant breastfeed woman . History colostomy . Current diagnosis indeterminate colitis , Crohn 's disease , ischemic colitis , fulminant colitis and/or toxic megacolon patient ulcerative colitis limit rectum ( ulcerative proctitis ) . Hepatitis B , C HIV . History cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>tralokinumab</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>moderate severe ulcerative colitis</keyword>
</DOC>